SGLT2 inhibitors (SGLT2i) provides nephroprotective benefits in to human patients with DKD, presumably by suppressing HIF1A and stimulating HIF2A, which in turn augments erythropoiesis44–47. Here, EPAS1 is linked to diabetic kidney disease.